New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 21, 2012
10:00 EDTINFI, BRFS, WAIR, RLGY, LNCO, CELG, BEAV, THLD, PXD, LINE, BIIB, YUM, RPRX, MPLXOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: BE Aerospace (BEAV) initiated with an Outperform at Imperial Capital... BRF Brasil Foods (BRFS) initiated with a Buy at Citigroup... Biogen (BIIB) initiated with a Buy at Brean Capital... Celgene (CELG) initiated with a Buy at Brean Capital... Infinity Pharmaceuticals (INFI) initiated with an Outperform at RBC Capital... LINN Energy (LINE) initiated with a Neutral at Goldman... LINN Energy (LINE) initiated with an Outperform at RW Baird... LinnCo (LNCO) initiated with a Buy at UBS... LinnCo (LNCO) initiated with a Neutral at Credit Suisse... MPLX (MPLX) initiated with a Buy at Citigroup... Matrix Service (MTRX) initiated with a Buy at DA Davidson... Pioneer Natural (PXD) initiated with a Buy at Citigroup... Realogy (RLGY) initiated with a Neutral at Citigroup... Repros Therapeutics (RPRX) initiated with a Buy at Roth Capital... Threshold Pharmaceuticals (THLD) initiated with a Buy at Brean Capital... Wesco Aircraft (WAIR) initiated with an In-Line at Imperial Capital... Yum! Brands (YUM) initiated with an Outperform at Macquarie
News For BEAV;BRFS;BIIB;CELG;INFI;LINE;LNCO;MPLX;PXD;RLGY;RPRX;THLD;WAIR;YUM From The Last 14 Days
Check below for free stories on BEAV;BRFS;BIIB;CELG;INFI;LINE;LNCO;MPLX;PXD;RLGY;RPRX;THLD;WAIR;YUM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
April 15, 2014
12:14 EDTPXDPioneer Natural to recognize noncash loss of approximately $30M
Pioneer Natural Resources announced that the company closed its previously announced sale of its Alaska subsidiary to Caelus Energy Alaska for cash proceeds of $300M, subject to normal closing adjustments, plus other consideration. The company expects to recognize a noncash loss of approximately $30M associated with the sale when it reports earnings for 1Q14.
07:22 EDTPXDGlobal Hunter Securities to hold a conference
1:1 Dallas Energy Day is being held in Dallas on April 15.
April 14, 2014
09:46 EDTBIIBBiogen hugs support at critical technical juncture, levels to watch
Subscribe for More Information
08:45 EDTPXDPioneer Natural price target raised to $212 from $206 at Howard Weil
Howard Weil raised its price target for Pioneer Natural shares to $212 and keeps a Sector Perform rating on the stock.
07:33 EDTBIIBBiogen to present Plegridy, Tecfidera data at AAN annual meeting
Subscribe for More Information
07:23 EDTYUMJapan sees first bird flu outbreak since 2011, Mainichi reports
Subscribe for More Information
07:04 EDTPXDStephens to hold a field trip
Subscribe for More Information
April 11, 2014
12:42 EDTLNCOOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
10:15 EDTBIIBBiogen heads for test of $280 area
The shares are heading lower after an early bounce attempt and are now just above the session low at $280.13. As noted yesterday, a break below $280 would confirm topping in the shares. Support below $280 is at $273.45. Resistance is at $285.
09:03 EDTCELGCelgene shares can unlock big value, says RBC Capital
Subscribe for More Information
06:31 EDTLNCOLinnCo upgraded to Buy from Neutral at UBS
Subscribe for More Information
April 10, 2014
15:13 EDTBIIBBiogen tumbles, nearing important test of support
Subscribe for More Information
10:05 EDTCELGCelgene CEO Hugin says 'excited' about guidance for the year
Subscribe for More Information
09:00 EDTBIIBBiogen May volatility elevated at 43 into Q1 and revenue outlook
Subscribe for More Information
08:10 EDTCELGCelgene likely to prevail in patent case, says Stifel
Subscribe for More Information
07:33 EDTCELGCelgene antibody could open door for new area of focus, says Wells Fargo
Wells Fargo believes that Celgene is developing an anti-CD47 antibody that could enable the company to enter the immune-oncology space and pivot into biologics. The firm views the stock as undervalued, and believes that Celgene has many viable opportunities that could enable the stock to rise over the long-term. The firm keeps an Outperform rating on the shares and identifies it as a top pick.
07:31 EDTBIIBBiogen names Adam Koppel as SVP, Chief Strategy Officer
Subscribe for More Information
07:08 EDTBIIBBiogen announces positive top-line efficacy, safety results from Phase 3 trial
Biogen Idec and Swedish Orphan Biovitrum AB released positive top-line results of the Kids A-LONG Phase 3 clinical study that evaluated the safety and efficacy of Eloctate, an investigational recombinant factor VIII Fc fusion protein product candidate, in children with severe haemophilia A. Eloctate was generally well-tolerated and no inhibitors were detected. Efficacy analyses showed twice-weekly prophylactic dosing with Eloctate maintained low bleeding rates in children.
April 9, 2014
17:25 EDTINFIPoint72 Asset lowers passive stake in Infinity Pharmaceuticals to 7.1% from 7.5%
Subscribe for More Information
12:12 EDTCELGMarkman documents appear to favor Celgene, The Street says
Public documents for the pre-trial Markman hearing appear to favor Celgene over Natco, the generic drugmaker challenging some of Celgene's Revlimid patents, The Street's Adam Feuerstein reports. Shares of Celgene are up 5% to $145.33 in mid-day trading. Reference Link
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use